Personalis provides researchers and clinicians accurate DNA sequencing and interpretation of human genomes. We support researchers engaging in case-control, family-based, or proband-only genomic studies of disease, pharmacogenomics, and cancer. Our ACE (Accuracy and Content Enhanced) Technology™ supplements a standard exome or genome, substantially increasing its medically-relevant coverage and accuracy. Personalis builds on this enhanced sequencing foundation with innovative algorithms and proprietary databases for alignment, variant calling, annotation, and analysis.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/07/13 | $22,000,000 | Series B |
Abingworth Mohr Davidow Ventures Wellington Shields & Co. | undisclosed |
| 01/13/15 | $33,000,000 | Series C |
Abingworth Mohr Davidow Ventures | undisclosed |
